Changes are coming to our lives and world that may rival the industrial and internet revolutions. Jeremy Schwartz and Kara Marciscano discuss the BioRevolution already underway and identify the range of business sectors we believe are best positioned to benefit.
No matter your economic forecast for the near future, Brian Manby explains why we think the WisdomTree U.S. MidCap Fund (EZM) could be a part of it.
Finding investments with low price-to-earnings ratios can be a challenge in 2021. Jeff Weniger explains how to find them in emerging markets.
The interest rate environment that was a tailwind to growth stocks in 2020 is unlikely to reoccur in 2021, and it may become a headwind should rates continue to rise. Against this backdrop, Matt Wagner makes the case to allocate toward mid- and small-cap dividend strategies.
In today’s market, we believe it is paramount to defend against exorbitant valuations and segments that bleed upward along the size spectrum, all while preserving profitability. Fortunately, the WisdomTree U.S. MidCap Fund can do all three, and it has a 14-year history to prove it. Brian Manby discusses.
Many investors believe that there will be inflation post-COVID-19. Against this backdrop, Jeff Weniger makes the case that equity investors should consider positioning towards small- and mid-cap strategies.